Drug
Oplunofusp clinical trials
Also written DAS181.
- studies test it
- 14
- open now
- 1
- in phase 3
- 2
- first study started
- 2007
Keep track of what changes. Save the oplunofusp studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
14 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2019 | 1 |
| 2020 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 7
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 4
Ansun Biopharma, Inc. (10) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Renmin Hospital of Wuhan University (1)
Studies
Open first, then newest update. How each study uses oplunofusp is read from its arms, and is right about nine times in ten.
Testing it · 14
- Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT StudyRecruitingPhase 3Ansun Biopharma, Inc.NCT03808922Written as DAS181
- DAS181 for STOP COVID-19WithdrawnPhase 2/3Ansun Biopharma, Inc.NCT04354389Written as DAS181
- DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)Status unknownPhase 2Ansun Biopharma, Inc.NCT04298060Written as DAS181
- DAS181 for Severe COVID-19: Compassionate UseCompletedNot applicableRenmin Hospital of Wuhan UniversityNCT04324489Written as DAS181
- DAS181 in Patients With ParainfluenzaWithdrawnPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT01441024Written as DAS181
- DAS181 Single Dose Escalation Study in Healthy AdultsCompletedPhase 1Ansun Biopharma, Inc.NCT00876161Written as DAS181
- Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired InfluenzaCompletedPhase 2Ansun Biopharma, Inc.NCT01740063Written as DAS181-F02 formulation
- A Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or BronchiectasisCompletedPhase 1Ansun Biopharma, Inc.NCT01113034Written as DAS181 dry powder, formulation F02
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental OxygenCompletedPhase 2Ansun Biopharma, Inc.NCT01644877Written as DAS181 dry powder, formulation F02
- An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) InfectionCompletedPhase 2Ansun Biopharma, Inc.NCT01924793Written as DAS181-F02 Dry Powder in Bulk
- Influenza Antiviral DAS-181-F04 in Healthy AdultsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01651494Written as DAS181
- Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed InfluenzaCompletedPhase 2Ansun Biopharma, Inc.NCT01037205Written as DAS181 dry powder, formulation F02
- Influenza Antiviral DAS181-F03CompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01173224Written as DAS181
- Single Dose Escalating Study of DAS181 in AdultsCompletedPhase 1Ansun Biopharma, Inc.NCT00527865Written as DAS181
Codes
What other systems call oplunofusp · ClinicalTrials.gg INT005207
- MeSH (NLM) C525612oplunofuspOne source NLM
- UNII (FDA) 227R1C272QOPLUNOFUSPConfirmed FDA, NLM
- NCI Thesaurus C113163OplunofuspOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C525612 | oplunofusp | One source NLM |
| UNII (FDA) | 227R1C272Q | OPLUNOFUSP | Confirmed FDA, NLM |
| NCI Thesaurus | C113163 | Oplunofusp | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.